> CureVac unveiled leadership changes. Ingmar Hoerr is set to transition to the chairman role, leaving the CEO seat free for Daniel Menichella. Release
> InflaRx netted $57.1 million in a stock offering. The financing sets InflaRx up to run midphase trials of antihuman C5a monoclonal antibody IFX-1. Statement
> Memo Therapeutics raised CHF 5 million ($5 million) to advance its antibody candidates. Release
> Motif Bio hired Stephanie Noviello, M.D., to support its filing for approval of iclaprim in Europe. Noviello joins the antibiotic drug developer from Bristol-Myers Squibb. Statement (PDF)
> French authorities cleared Advicenne to start a phase 2/3 trial of its lead candidate in cystinuria, a rare inherited disease that causes recurrent kidney stone formation. Release
> Lundbeck gave up trying to fix a manufacturing problem that has stymied commercialization of Carnexiv. The FDA approved the seizure drug in 2016 but Lundbeck subsequently ran into a problem it has been unable to solve. Lundbeck is now looking to divest the asset. Statement (PDF)